• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Aehr Test Systems Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

    7/14/23 8:16:49 AM ET
    $ACAD
    $AEHR
    $AIMD
    $ARBB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Electrical Products
    Industrials
    Get the next $ACAD alert in real time by email

    Gainers

    • Ainos, Inc. (NASDAQ:AIMD) shares surged 108.2% to $1.52 in pre-market trading after gaining around 7% on Thursday.
    • Intuitive Machines, Inc. (NASDAQ:LUNR) shares gained 29.1% to $11.02 in pre-market trading. Intuitive Machines is closing in on delivering its Nova-C lunar lander to Florida for launch. The company said on Thursday that it has successfully conducted a complete spacecraft test run of the lander.
    • Nikola Corporation (NASDAQ:NKLA) shares rose 20.7% to $2.68 in pre-market trading after gaining over 60% on Thursday. The company and BayoTech announced an agreement to advance reliable hydrogen supply for zero-emission commercial fuel cell electric vehicle fleets.
    • ARB IOT Group Limited (NASDAQ:ARBB) shares rose 20.3% to $3.92 in pre-market trading after gaining around 12% on Thursday.
    • ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) gained 20.2% to $31.00 in pre-market trading. Acadia Pharmaceuticals acquired ex-North American rights to trofinetide and global rights to Neuren's NNZ-2591 in Rett syndrome and Fragile X syndrome.
    • OKYO Pharma Limited (NASDAQ:OKYO) shares climbed 18.8% to $1.28 in pre-market trading after adding around 4% on Thursday.
    • 1847 Holdings LLC (NYSE:EFSH) rose 16.8% to $0.2920 in pre-market trading. 1847 projects revenue of $20 million for the second quarter.
    • Taoping Inc. (NASDAQ:TAOP) rose 16.3% to $0.6499 in pre-market trading after declining around 7% on Thursday. Taoping recently reported 1H 2023 contract revenue of roughly $14.65 million, up 95% year over year.
    • GT Biopharma, Inc. (NASDAQ:GTBP) shares gained 13.9% to $0.3201 in pre-market trading.
    • Aehr Test Systems (NASDAQ:AEHR) gained 4.4% to $43.23 in pre-market trading as the company reported better-than-expected results for its fourth quarter. The company said it sees FY24 revenue to be at least $100 million and GAAP net income of at least $28 million.

    Losers

    • Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) fell 67.6% to $3.08 in pre-market trading after the company announced plans to discontinue enrollment in Phase 1/2 study and terminate development of THE-630 in patients with GIST.
    • Leslie's, Inc. (NASDAQ:LESL) fell 27.8% to $6.87 in pre-market trading after the company released preliminary results for its fiscal third quarter and announced a CFO transition. The company said it expects fiscal third-quarter revenue to come in at $611 million versus estimates of $703.74 million and seed adjusted earnings in a range of 39 cents to 41 cents per share versus estimates of 69 cents per share. Leslie's also announced that CFO Steve Weddell is stepping down from his role, effective Aug. 7.
    • EdtechX Holdings Acquisition Corp. II (NASDAQ:EDTX) fell 14.1% to $37.16 in pre-market trading after jumping 203% on Thursday.
    • Fresh Vine Wine, Inc. (NASDAQ:VINE) fell 9.7% to $0.5299 in pre-market trading after gaining over 12% on Thursday.
    • Nokia Oyj (NYSE:NOK) shares fell 9.4% to $3.94 in pre-market trading after the company reduced net sales guidance and narrowed its operating margin outlook for 2023.
    • Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) fell 8.7% to $0.3205 in pre-market. Aridis recently announced FDA Qualified Infectious Disease Product Designation for AR-301.
    • Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) shares fell 8.2% to $5.27 in pre-market trading after the company posted a loss for the second quarter.
    • Jiuzi Holdings, Inc. (NASDAQ:JZXN) shares fell 8.1% to $3.73 in pre-market trading after climbing over 45% on Thursday.
    • Ault Alliance, Inc. (NYSE:AULT) fell 8.1% to $3.87 in pre-market trading after declining over 20% on Thursday. Ault Alliance recently announced a second partial distribution of TOG Securities of approximately $0.37 for each share of Ault Alliance common stock.
    • Evogene Ltd. (NASDAQ:EVGN) fell 7.1% to $1.31 in pre-market trading after gaining 12% on Thursday.

     

    Now Read This: Top 5 Materials Stocks That Should Keep You Up At Night

    Get the next $ACAD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAD
    $AEHR
    $AIMD
    $ARBB

    CompanyDatePrice TargetRatingAnalyst
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/24/2026$33.00Outperform
    Wolfe Research
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/23/2026$35.00Neutral → Outperform
    Mizuho
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    Nokia Corporation Sponsored
    $NOK
    2/9/2026$8.00Overweight
    Morgan Stanley
    Ericsson
    $ERIC
    2/9/2026$11.00Equal-Weight
    Morgan Stanley
    Leslie's Inc.
    $LESL
    1/15/2026$1.50Equal-Weight → Underweight
    Morgan Stanley
    Nokia Corporation Sponsored
    $NOK
    1/15/2026Equal-Weight → Overweight
    Morgan Stanley
    Intuitive Machines Inc.
    $LUNR
    1/9/2026$20.00Buy → Hold
    Stifel
    More analyst ratings

    $ACAD
    $AEHR
    $AIMD
    $ARBB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    9/18/23 10:47:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    9/18/23 10:40:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAYBUE issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

    3/13/23 10:37:07 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEHR
    $AIMD
    $ARBB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blitzer Michael bought $2,190,435 worth of shares (241,080 units at $9.09), increasing direct ownership by 14% to 1,931,248 units (SEC Form 4)

    4 - Intuitive Machines, Inc. (0001844452) (Issuer)

    11/13/25 7:15:03 PM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    Large owner Ase Test, Inc. bought 29,476 shares (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    6/25/25 6:03:05 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Iskander Anthony A bought $49,916 worth of shares (63,995 units at $0.78), increasing direct ownership by 3,200% to 65,995 units (SEC Form 4)

    4 - Leslie's, Inc. (0001821806) (Issuer)

    5/15/25 4:05:40 PM ET
    $LESL
    Other Specialty Stores
    Consumer Discretionary

    $ACAD
    $AEHR
    $AIMD
    $ARBB
    SEC Filings

    View All

    SEC Form 6-K filed by Ericsson

    6-K - ERICSSON LM TELEPHONE CO (0000717826) (Filer)

    2/24/26 7:29:18 AM ET
    $ERIC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    SEC Form 6-K filed by OKYO Pharma Limited

    6-K - OKYO Pharma Ltd (0001849296) (Filer)

    2/23/26 11:00:27 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Nokia Corporation Sponsored

    6-K - NOKIA CORP (0000924613) (Filer)

    2/20/26 9:57:58 AM ET
    $NOK
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ACAD
    $AEHR
    $AIMD
    $ARBB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on ACADIA Pharmaceuticals with a new price target

    Wolfe Research initiated coverage of ACADIA Pharmaceuticals with a rating of Outperform and set a new price target of $33.00

    2/24/26 7:44:56 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACADIA Pharmaceuticals upgraded by Mizuho with a new price target

    Mizuho upgraded ACADIA Pharmaceuticals from Neutral to Outperform and set a new price target of $35.00

    2/23/26 8:28:41 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on OKYO Pharma with a new price target

    Piper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00

    2/20/26 8:25:04 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACAD
    $AEHR
    $AIMD
    $ARBB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Altemus Stephen J sold $1,389,456 worth of shares (86,803 units at $16.01), decreasing direct ownership by 7% to 1,176,246 units (SEC Form 4)

    4 - Intuitive Machines, Inc. (0001844452) (Issuer)

    2/13/26 8:47:01 PM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    Officer Jones Anna Chiara sold $292,559 worth of shares (16,779 units at $17.44), decreasing direct ownership by 7% to 209,200 units (SEC Form 4)

    4 - Intuitive Machines, Inc. (0001844452) (Issuer)

    2/13/26 8:46:48 PM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    SVP and CFO Mcgrath Peter sold $445,333 worth of shares (25,541 units at $17.44), decreasing direct ownership by 6% to 425,800 units (SEC Form 4)

    4 - Intuitive Machines, Inc. (0001844452) (Issuer)

    2/13/26 8:46:35 PM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    $ACAD
    $AEHR
    $AIMD
    $ARBB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The New Space Race Isn't About Rockets. It's About Who Builds Them

    VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The global commercial space launch market, valued at $8.2 billion in 2024, is projected to nearly quadruple to $31.9 billion by 2034 as small satellite demand accelerates[1]. Congress approved $839 billion in defense spending for fiscal 2026, including $4 billion for missile warning and tracking satellites and $13.4 billion to integrate space and missile defense systems[2]. Companies positioned at the intersection of commercial launch and national security include Starfighters Space (NYSE-A: FJET), Rocket Lab (NASDAQ:RKLB), L3Harris Technologies (NYSE:LHX), Intuitive Machines (NASDAQ:LUNR) and N

    2/24/26 11:13:16 AM ET
    $LHX
    $LUNR
    $NOC
    Industrial Machinery/Components
    Industrials
    Military/Government/Technical

    Notice of the Annual General Meeting of shareholders 2026 of Telefonaktiebolaget LM Ericsson

    STOCKHOLM, Feb. 24, 2026 /PRNewswire/ -- The shareholders of Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) (reg. no 556016-0680) (the "Company" or "Ericsson") are invited to participate in the Annual General Meeting of shareholders ("AGM") to be held on Tuesday, March 31, 2026 at 2:00 PM CEST at the Company's premises: Open Box, Grönlandsgatan 8, Kista/Stockholm. Registration for the AGM starts at 1:00 PM CEST. Shareholders may also exercise their voting rights by post before the AGM. The AGM will be conducted in Swedish and simultaneously translated into English.Registration and notice of participationA) Participation at the meeting venueShareholders who wish to attend the meeting venue in

    2/24/26 2:47:00 AM ET
    $ERIC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fireside Chat: Monday, March 2, 2026 at 11:10 a.m. Eastern Time in Boston, MA The Citizens Life Sciences Conference Fireside Chat: Wednesday, March 11, 2026 at 1:05 p.m. Eastern Time in Miami Beach, FL Live webcasts will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceuticals Acadia is committed to turning scientific promise into meaningful innovati

    2/23/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEHR
    $AIMD
    $ARBB
    Leadership Updates

    Live Leadership Updates

    View All

    Global technology leaders launch Trusted Tech Alliance

    In a time when the world is divided, 15 leading global companies from 10 countries are coming together to serve customers around the worldSTOCKHOLM, Feb. 13, 2026 /PRNewswire/ -- Today, at the Munich Security Conference, 15 companies from Africa, Asia, Europe, and North America announced the launch of the Trusted Tech Alliance (TTA), a group of likeminded global technology providers coming together to work across borders, and based on a shared set of principles for a trusted technology stack – from connectivity, cloud infrastructure, and semiconductors to software and AI. These principles are designed to ensure that, regardless of a supplier's nationality, companies in this Alliance will ad

    2/13/26 12:29:00 PM ET
    $ERIC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

    The collaboration is supported by a pan-European EUREKA grant, with participation of the Weizmann Institute of Science REHOVOT, Israel and MUNICH, Germany, Feb. 11, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerate drug discovery for complex disorders, and LMU University Hospital Munich, today announced a collaboration aiming to accelerate the devel

    2/11/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACAD
    $AEHR
    $AIMD
    $ARBB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Intuitive Machines Inc.

    SC 13D/A - Intuitive Machines, Inc. (0001844452) (Subject)

    11/20/24 5:01:02 PM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by Intuitive Machines Inc.

    SC 13G/A - Intuitive Machines, Inc. (0001844452) (Subject)

    11/14/24 7:05:51 PM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    $ACAD
    $AEHR
    $AIMD
    $ARBB
    Financials

    Live finance-specific insights

    View All

    Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

    Zoom conference call scheduled for March 5, 2026, 9:00 AM ET REHOVOT, Israel, Feb. 19, 2026 /PRNewswire/ -- Evogene Ltd . (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the fourth quarter and full year 2025, on Thursday, March 5, 2026. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene The entire conference will be

    2/19/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Leslie's, Inc. Announces First Quarter 2026 Financial Results

    Sales and adjusted EBITDA in-line with Company expectations, reiterates full year guide 80 underperforming stores closed during Q1 2026 Improved inventory efficiency with ~23% reduction year-over-year PHOENIX, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Leslie's, Inc. (NASDAQ:LESL), the largest and most trusted direct-to-customer brand in the U.S. pool and spa care industry serving residential customers and pool professionals nationwide, today announced its financial results for the fiscal first quarter 2026. Jason McDonell, Chief Executive Officer, said, "Leslie's transformation journey is gaining momentum as we execute with precision and urgency. Our first quarter results met our expectations,

    2/17/26 4:15:00 PM ET
    $LESL
    Other Specialty Stores
    Consumer Discretionary

    Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    Company to host conference call and webcast on Wednesday, February 25, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until May 24, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive

    2/4/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care